DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its completed Phase 3 Lymphoseek studies in breast cancer and melanoma are being presented at the 32nd Congress of the European Society of Surgical Oncology (ESSO) in Valencia, Spain, from September 19-21, 2012. During the Breast Cancer III - Technical Aspect session, Frederick Cope, Ph.D., Navidea’s Senior Vice President of Pharmaceutical Research and Drug Development, will make an oral presentation of a meta-analysis comparison of data from Lymphoseek Phase 3 breast cancer studies and a meta-analysis of published literature on three colloidal agents evaluating two key clinical performance characteristics in intraoperative lymphatic mapping. In addition, Dr. Cope will present a poster of the results from combined Phase 3 clinical trials in breast cancer and melanoma demonstrating a positive correlation between preoperative imaging (lymphoscintigraphy) using Lymphoseek and the intraoperative/surgical findings of tumor-draining lymph nodes.
